Details for: VOTRIENT
Company: NOVARTIS PHARMACEUTICALS CANADA INC
| DIN | DIN name | Active Ingredient(s) | Strength | Dosage Form | Route of Administration |
|---|---|---|---|---|---|
| 02352303 | VOTRIENT | PAZOPANIB (PAZOPANIB HYDROCHLORIDE) | 200 MG | TABLET | ORAL |
Summary Reports
Summary Basis of Decision
Summary Safety Review - VOTRIENT (pazopanib) - Assessing the Potential Risk of Accumulation of Fluid Around the Heart (Pericardial Effusion)
Summary Safety Review - Vascular Endothelial Growth Factor Receptor Inhibitors - Thrombotic Microangiopathy
Summary Safety Review - VOTRIENT (pazopanib) - Assessing the Potential Risk of Accumulation of Fluid Around the Heart (Pericardial Effusion)
Summary Safety Review - Vascular Endothelial Growth Factor Receptor Inhibitors - Thrombotic Microangiopathy
Consumer Information
The Consumer Information is not yet available in the Drug and Health Product Register. Try searching on the active ingredient(s) to find other similar products.